Legal & General Group
RXRX icon

Legal & General Group’s Recursion Pharmaceuticals RXRX Stock Holding History

Legal & General Group’s Portfolio RXRX Stock Details RXRX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$1.31M Buy
356,653
+14,228
+4% +$47.4K ﹤0.01% 2113
2026
Q1 		$1.05M Sell
342,425
-22,275
-6% -$86.1K ﹤0.01% 2126
2025
Q4 		$1.49M Buy
364,700
+11,092
+3% +$54.9K ﹤0.01% 2088
2025
Q3 		$1.73M Buy
353,608
+38,823
+12% +$204K ﹤0.01% 2040
2025
Q2 		$1.59M Buy
314,785
+66,803
+27% +$328K ﹤0.01% 2053
2025
Q1 		$1.31M Sell
247,982
-5,444
-2% -$39.7K ﹤0.01% 2080
2024
Q4 		$1.71M Buy
253,426
+67,953
+37% +$457K ﹤0.01% 2040
2024
Q3 		$1.22M Buy
185,473
+4,330
+2% +$31K ﹤0.01% 2164
2024
Q2 		$1.36M Buy
181,143
+29,404
+19% +$256K ﹤0.01% 2094
2024
Q1 		$1.51M Buy
151,739
+22,118
+17% +$246K ﹤0.01% 2042
2023
Q4 		$1.28M Buy
129,621
+11,571
+10% +$82.5K ﹤0.01% 2117
2023
Q3 		$903K Buy
118,050
+6,465
+6% +$64.5K ﹤0.01% 2219
2023
Q2 		$834K Buy
111,585
+11,035
+11% +$77.2K ﹤0.01% 2287
2023
Q1 		$671K Buy
100,550
+6,580
+7% +$52.2K ﹤0.01% 2249
2022
Q4 		$725K Buy
93,970
+4,463
+5% +$43.8K ﹤0.01% 2240
2022
Q3 		$952K Sell
89,507
-22,830
-20% -$231K ﹤0.01% 2162
2022
Q2 		$914K Buy
112,337
+47,649
+74% +$319K ﹤0.01% 2194
2022
Q1 		$463K Buy
64,688
+43,935
+212% +$467K ﹤0.01% 2413
2021
Q4 		$355K Buy
20,753
+18,047
+667% +$340K ﹤0.01% 2523
2021
Q3 		$62K Buy
2,706
+655
+32% +$18.6K ﹤0.01% 2929
2021
Q2 		$75K Buy
+2,051
New +$60.7K ﹤0.01% 2821

Other funds holding RXRX

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
AIM
ARK Investment Management St. Petersburg, Florida $15.4B AUM 50.29% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Vanguard Portfolio Management
Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM
Baillie Gifford & Co
Baillie Gifford & Co Edinburgh, United Kingdom $110B AUM 4.8% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
SoftBank Group
SoftBank Group Tokyo, Japan $18.2B AUM 177.65% 1-Year Est. Return
MCMU
MIC Capital Management (UK) London, United Kingdom $394M AUM 25.64% 1-Year Est. Return
UBS Group
UBS Group Zurich, Switzerland $786B AUM 40.34% 1-Year Est. Return

Legal & General Group's RXRX Position: Q2 2026 in Review

Legal & General Group increased its Recursion Pharmaceuticals (RXRX) stake by 4.2% in Q2 2026, buying an estimated $47.4K and bringing the position to 356,653 shares worth $1.31M. The position accounts for ﹤0.01% of the portfolio, ranked #2113.

Legal & General Group first reported a position in RXRX in Q2 2021 and has held it in 21 quarters since. The position peaked at $1.73M in Q3 2025. 343 funds tracked by Wall St. Rank hold RXRX as of Q2 2026.

  • Legal & General Group held 356,653 shares of Recursion Pharmaceuticals worth $1.31M as of Q2 2026.
  • Legal & General Group bought 14,228 Recursion Pharmaceuticals shares in Q2 2026, an estimated $47.4K.
  • Recursion Pharmaceuticals made up ﹤0.01% of Legal & General Group's portfolio in Q2 2026, its #2113 holding.
  • Legal & General Group first reported a position in Recursion Pharmaceuticals in Q2 2021 and has held it in 21 quarters since.
  • Legal & General Group's Recursion Pharmaceuticals position peaked at $1.73M in Q3 2025.
  • 343 funds tracked by Wall St. Rank held Recursion Pharmaceuticals as of Q2 2026.

Based on Legal & General Group's 13F filing for Q2 2026, filed 14 Aug 2026.